- New Danaher operating company created following completion of $21.4B 
  acquisition by Danaher Corporation

- Previously GE Healthcare Life Sciences, Cytiva will help accelerate growth 
  and innovation in biological therapies

- Leading life sciences brands such as AKTA, Amersham, HyClone, MabSelect and 
  Whatman are part of Cytiva

Cytiva, a global provider of technologies and services that help advance and 
accelerate the development and manufacture of therapeutics, launches today. 
Previously GE Healthcare Life Sciences, Cytiva has nearly 7,000 employees and 
operations in 40 countries and is part of the Danaher Corporation Life Sciences 
platform. 

Logo - https://mma.prnewswire.com/media/1138636/cytiva_Logo.jpg 

Emmanuel Ligner, President of Cytiva, says: "Our foundation of scientific 
expertise, our team, and our solid customer base place Cytiva in the right 
position to invest, develop, and accelerate growth in the industry. Our passion 
for helping bring life-changing therapies to patients is unwavering, and we 
will continue to introduce innovative technologies to the market which improve 
productivity for our customers." 

Cytiva experts and technologies enabled breakthroughs in science and medicine 
that have shaped today's biotechnology industry. In 2019, more than 75 percent 
of the biological therapies approved by the United States Food and Drug 
Administration relied on Cytiva's technologies for manufacturing. Additionally, 
Cytiva technology has contributed in the nascent area of cell and gene 
therapies and has done so since the first successful pediatric trial of CAR-T 
therapy in 2012. This area continues to have great potential and currently, 
there are more than 1,000 regenerative medicine clinical trials underway 
globally[1]. 

Accelerating growth, productivity, and innovation in the sector are major 
strategic focus areas for the company, as global demand for personalized and 
advanced biological therapies is ever-increasing. Cytiva drives 
customer-centered innovation, from idea to commercial development stages, with 
facilities across Asia, Europe, and the Americas. It also has centers for 
customer collaboration and training to enable the development of new therapies, 
such as the Testa Center in Uppsala, Sweden and with the University of 
Technology at Sydney.

Cytiva will also continue to pursue collaborations for research, such as the 
center for advanced biological innovation and manufacturing in Boston with 
Harvard, MIT, teaching hospitals, and industry partners Fujifilm Diosynth 
Biotechnologies, and Alexandria Real Estate Equities, Inc.

Cytiva's diverse portfolio includes well-recognized brands such as AKTA, 
Amersham, Biacore, FlexFactory, HyClone, MabSelect, Sefia, Whatman, Xcellerex 
and Xuri. The portfolio spans a full range of instruments, consumables, digital 
and enterprise solutions and services for research, process development, and 
complete manufacturing workflows that scale according to customers' needs. 

About Cytiva

Cytiva is a 3.3 billion USD global life sciences leader with nearly 7000 
associates operating in 40 countries dedicated to advancing and accelerating 
therapeutics. As a trusted partner to customers that range in scale and scope, 
Cytiva brings speed, efficiency and capacity to research and manufacturing 
workflows, enabling the development, manufacture and delivery of transformative 
medicines to patients. Visit www.cytiva.com for more. 

[1] The Alliance for Regenerative Medicine Q3 2019 Quarterly Report  ( 
https://c212.net/c/link/?t=0&l=en&o=2762961-1&h=2991931794&u=https%3A%2F%2Falliancerm.org%2Fpublication%2Fq3-2019-data-report%2F&a=The+Alliance+for+Regenerative+Medicine+Q3+2019+Quarterly+Report 
)

SOURCE:  Cytiva

CONTACT: Dodi Axelson
         Dodi.axelson@ge.com
         +46730958191